Discovery of DWP213388, a Potent ITK and BTK Dual Target Inhibitor with Excellent Efficacy, As a Treatment for Autoimmune Diseases

被引：0
|
作者：
Jung, Jae Hun [1 ]
Eom, Deokki [1 ]
Jeon, Seong-Uk [1 ]
Shin, Yong Dae [1 ]
Kim, Wolyoung [1 ]
Jung, Jaehyun [1 ]
Li, Qingri [1 ]
Hyun, Hyaejung [1 ]
Park, Joon Seok [2 ]
机构：
[1] Daewoong Pharmaceut, Yongin, South Korea
[2] Daewoong Pharmaceut, Seoul, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
37
引用
收藏
页数：1
相关论文
共 9 条
  • [1] Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd
    Eom, Deokki
    Jung, Jae Hun
    Kim, Eun Kyung
    Kim, Wolyoung
    Li, Qingri
    Jung, Jaehyun
    Im, Sohee
    Shin, Yong Dae
    Hyun, Hyaejung
    Park, Joon Seok
    BLOOD, 2019, 134
  • [2] Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases
    Shin, Yong Dae
    Jung, Jae-Hun
    Kim, Eun Kyung
    Im, Sohee
    Jun, Sunah
    Kim, NamYoun
    Jeong, SeungHwarn
    Hyun, Hyaejung
    Park, Joon Seok
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] Discovery of M2951: A selective, covalent inhibitor of BTK for the treatment of autoimmune diseases
    Goutopoulos, Andreas
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [4] Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
    Caldwell, Richard D.
    Qiu, Hui
    Askew, Ben C.
    Bender, Andrew T.
    Brugger, Nadia
    Camps, Montserrat
    Dhanabal, Mohanraj
    Dutt, Vikram
    Eichhorn, Thomas
    Gardberg, Anna S.
    Goutopoulos, Andreas
    Grenningloh, Roland
    Head, Jared
    Healey, Brian
    Hodous, Brian L.
    Huck, Bayard R.
    Johnson, Theresa L.
    Jones, Christopher
    Jones, Reinaldo C.
    Mochalkin, Igor
    Morandi, Federica
    Ngan Nguyen
    Meyring, Michael
    Potnick, Justin R.
    Santos, Dusica Cvetinovic
    Schmidt, Ralf
    Sherer, Brian
    Shutes, Adam
    Urbahns, Klaus
    Follis, Ariele Viacava
    Wegener, Ansgar A.
    Zimmerli, Simone C.
    Liu-Bujalski, Lesley
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 7643 - 7655
  • [5] Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
    Farmer, Luc J.
    Ledeboer, Mark W.
    Hoock, Thomas
    Arnost, Michael J.
    Bethiel, Randy S.
    Bennani, Youssef L.
    Black, James J.
    Brummel, Christopher L.
    Chakilam, Ananthsrinivas
    Dorsch, Warren A.
    Fan, Bin
    Cochran, John E.
    Halas, Summer
    Harrington, Edmund M.
    Hogan, James K.
    Howe, David
    Huang, Hui
    Jacobs, Dylan H.
    Laitinen, Leena M.
    Liao, Shengkai
    Mahajan, Sudipta
    Marone, Valerie
    Martinez-Botella, Gabriel
    McCarthy, Pamela
    Messersmith, David
    Namchuk, Mark
    Oh, Luke
    Penney, Marina S.
    Pierce, Albert C.
    Raybuck, Scott A.
    Rugg, Arthur
    Salituro, Francesco G.
    Saxena, Kumkum
    Shannon, Dean
    Shlyakter, Dina
    Swenson, Lora
    Tian, Shi-Kai
    Town, Christopher
    Wang, Jian
    Wang, Tiansheng
    Wannamaker, M. Woods
    Winquist, Raymond J.
    Zuccola, Harmon J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7195 - 7216
  • [6] Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases
    Peixoto, Christophe
    Joncour, Agnes
    Temal-Laib, Taoues
    Tirera, Amynata
    Dos Santos, Aurelie
    Jary, Helene
    Bucher, Denis
    Laenen, Wendy
    Fernandes, Anna Pereira
    Lavazais, Stephanie
    Delachaume, Carole
    Merciris, Didier
    Saccomani, Corinne
    Drennan, Michael
    Lopez-Ramos, Miriam
    Wakselman, Emanuelle
    Dupont, Sonia
    Borgonovi, Monica
    Magadan, Carlos Roca
    Monjardet, Alain
    Brys, Reginald
    De Vos, Steve
    Andrews, Martin
    Jimenez, Juan-Miguel
    Amantini, David
    Desroy, Nicolas
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (07) : 5233 - 5258
  • [7] Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity
    Mao, Churu
    Fang, Jiebin
    Zou, Shijie
    Huang, Yun
    Chen, Xiaoming
    Ding, Xia
    Fang, Zhangyun
    Zhang, Ningjing
    Lou, Yijie
    Chen, Zhe
    Ding, Wanjing
    Ma, Zhongjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (22) : 20619 - 20638
  • [8] Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
    Flanagan, Mark E.
    Blumenkopf, Todd A.
    Brissette, William H.
    Brown, Matthew F.
    Casavant, Jeffrey M.
    Shang-Poa, Chang
    Doty, Jonathan L.
    Elliott, Eileen A.
    Fisher, Michael B.
    Hines, Michael
    Kent, Craig
    Kudlacz, Elizabeth M.
    Lillie, Brett M.
    Magnuson, Kelly S.
    McCurdy, Sandra P.
    Munchhof, Michael J.
    Perry, Bret D.
    Sawyer, Perry S.
    Strelevitz, Timothy J.
    Subramanyam, Chakrapani
    Sun, Jianmin
    Whipple, David A.
    Changelian, Paul S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) : 8468 - 8484
  • [9] Discovery of ARN-4079-a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis.
    Vankayalapati, Hariprasad
    Yerramreddy, Venkatakrishnareddy
    Bendele, Philip
    Bendele, Alison
    Issac, Rueban Jacob Anicattu
    Adluri, Ram Sudheer
    LoGrasso, Philip
    Kremer, Joel M.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S652 - S652
1